ShangPharma, a China-based pharmaceutical and biotechnology research and development outsourcing company, has appointed William Dai as chief financial officer (CFO). Kevin Penghui Chen, current CFO and chief operating officer (COO), will become president and continue his role as COO.
Dai has more than 17 years of experience in accounting, financial management, and the capital markets. Prior to ShangPharma, he served as CFO of China Nepstar Chain Drugstore in Shenzhen, China since January 2009. From 2006 to 2008, Dai was CFO and vice chair of the executive committee at MicroPort Medical in Shanghai, China. From 1993 to 2005, he held a variety of financial and senior managerial roles at multinational companies in China and the US.
Dai holds a MBA with an emphasis in finance from Michigan State University, and a bachelor’s degree in international business and English from Shanghai University’s College of International Business in Shanghai, China.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more